Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Phase 2 Study to Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03® or MF59®

NCT06560151 is registered in ClinicalTrials.gov with Biomedical Advanced Research and Development Authority as lead sponsor.

NCT NCT06560151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06560151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Phase 2 Study to Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03® or MF59®
Lead sponsor
Biomedical Advanced Research and Development Authority
Phase
Phase 2
Overall status
Completed
Start date
August 21, 2024
Completion date
June 11, 2025
Enrollment
1,380 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

influenza